Differences in proinflammatory activity of several immunomodulatory derivatives of muramyl dipeptide (MDP) with special reference to the mechanism of the MDP effects

[1]  K. Matsushima,et al.  An Interleukin-1/Tumor Necrosis Factor Inducible Inflammatory Cytokine, Interleukin-8 , 1990 .

[2]  M. Sticherling,et al.  IL-1 alpha or tumor necrosis factor-alpha stimulate release of three NAP-1/IL-8-related neutrophil chemotactic proteins in human dermal fibroblasts. , 1990, Journal of immunology.

[3]  A. Waage,et al.  Endotoxin, tumor necrosis factor-α and interleukin 1 induce interleukin 6 production in vivo , 1989 .

[4]  A. Cerami,et al.  Macrophage inflammatory proteins 1 and 2: members of a novel superfamily of cytokines , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  A. Cerami,et al.  Macrophage inflammatory protein-1: a prostaglandin-independent endogenous pyrogen. , 1989, Science.

[6]  L. Aarden,et al.  Interleukin 6 is involved in interleukin 1‐induced activities , 1988, European journal of immunology.

[7]  L. Kobzik,et al.  Recombinant granulocyte-macrophage colony-stimulating factor down-regulates expression of IL-2 receptor on human mononuclear phagocytes by induction of prostaglandin E. , 1988, Journal of immunology.

[8]  A. Goldberg,et al.  Tumor necrosis factor can induce fever in rats without activating protein breakdown in muscle or lipolysis in adipose tissue. , 1988, The Journal of clinical investigation.

[9]  W. Fiers,et al.  The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[10]  V. T. Ivanov,et al.  Structure, design, and synthesis of immunoactive peptides , 1987 .

[11]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[12]  S. Kusumoto,et al.  Adjuvant activity of 6-O-acyl-muramyldipeptides to enhance primary cellular and humoral immune responses in guinea pigs: dose-response and local reactions observed with selected compounds , 1986, Infection and immunity.

[13]  S. Kusumoto,et al.  Adjuvant activity of 6-O-acyl-muramyldipeptides to enhance primary cellular and humoral immune responses in guinea pigs: adaptability to various vehicles and pyrogenicity , 1986, Infection and immunity.

[14]  T. Hirofuji,et al.  Muramyl Dipeptide Induces Acute Joint Inflammation in the Mouse , 1986, Microbiology and immunology.

[15]  B. Beutler,et al.  Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1 , 1986, The Journal of experimental medicine.

[16]  S. Mizel,et al.  In vivo inflammatory activity of epidermal cell-derived thymocyte activating factor and recombinant interleukin 1 in the mouse. , 1986, The Journal of clinical investigation.

[17]  K. Mašek,et al.  Edemagenic activity of aqueous form of muramyl dipeptide (MDP) in rats. , 1985, Methods and findings in experimental and clinical pharmacology.

[18]  M. Flegel,et al.  The immunomodulatory property of a novel synthetic compound adamantylamide dipeptide. , 1984, Methods and findings in experimental and clinical pharmacology.

[19]  G. Riveau,et al.  Inhibition of endogenous pyrogen-induced fever by a muramyl dipeptide derivative. , 1984, The American journal of physiology.

[20]  A. Goldberg,et al.  Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. , 1983, The New England journal of medicine.

[21]  C. Dinarello,et al.  Role of arachidonate metabolism in the immunoregulatory function of human leukocytic pyrogen/lymphocyte-activating factor/interleukin 1. , 1982, Journal of immunology.

[22]  G. Riveau,et al.  Production of lymphocyte activating factor in the absence of endogenous pyrogen by rabbit or human leukocytes stimulated by a muramyl dipeptide derivative. , 1982, International journal of immunopharmacology.

[23]  K. Mašek,et al.  Arthritogenic activity of a synthetic immunoadjuvant, muramyl dipeptide , 1982, Infection and immunity.

[24]  E. Lederer,et al.  Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity , 1982, Infection and immunity.

[25]  C. Pearson,et al.  Adjuvant polyarthritis. V. Induction by N-acetylmuramyl-L-alanyl-D- isoglutamine, the smallest peptide subunit of bacterial peptidoglycan , 1981, The Journal of experimental medicine.

[26]  C. Pearson,et al.  Role of thymus for N-acetyl muramyl-L-alanyl-D-isoglutamine-induced polyarthritis and granuloma formation in euthymic and athymic nude rats or in neonatally thymectomized rats , 1981, Infection and immunity.

[27]  C. Dinarello,et al.  Effect of indomethacin on increased resistance to bacterial infection and on febrile responses induced by muramyl dipeptide. , 1980, The Journal of infectious diseases.

[28]  S. Kusumoto,et al.  Arthritis-inducing ability of a synthetic adjuvant, N-acetylmuramyl peptides, and bacterial disaccharide peptides related to different oil vehicles and their composition , 1980, Infection and immunity.

[29]  S. Nagao,et al.  Muramyl dipeptide-induced adjuvant arthritis , 1980, Infection and immunity.

[30]  E. Lederer,et al.  Modulation of the immune response by a synthetic adjuvant and analogs. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[31]  W. Fiers,et al.  Different pro-inflammatory profiles of interleukin 1 (IL 1) and tumor necrosis factor (TNF) in anin vivo model of inflammation , 2005, Agents and Actions.

[32]  K. Mašek,et al.  Some Immunopharmacological Properties of Adamantylamide Dipeptide (AdDP) , 1990 .

[33]  Y. Maeda.  Non-specific inflammatory responses augmented by neutral polysaccharides , 1989 .

[34]  C. Ucla,et al.  Induction of human interleukin 1 mRNA measured by collagenase‐ and prostaglandin E2‐stimulating activity in rheumatoid synovial cells , 1984, European journal of immunology.

[35]  A. Ford-hutchinson,et al.  The role of arachidonic acid oxygenation products in pain and inflammation. , 1984, Annual review of immunology.

[36]  O. Kohashi,et al.  A new model of experimental arthritis induced by an aqueous form of synthetic adjuvant in immunodeficient rate (SHR and nude rats). , 1981, Ryumachi. [Rheumatism].

[37]  S. Wahl,et al.  ADJUVANT ACTIVATION OF MACROPHAGE FUNCTIONS , 1980 .

[38]  E. Lederer,et al.  Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse. , 1979, International journal of immunopharmacology.